Schwartz MD - Search Results

1

Reassessing the Benefits and Harms of Risk-Reducing Medication Considering the Persistent Risk of Breast Cancer Mortality in Estrogen Receptor-Positive Breast Cancer.

Jayasekera J, Zhao A, Schechter C, Lowry K, Yeh JM, Schwartz MD, O'Neill S, Wernli KJ, Stout N, Mandelblatt J, Kurian AW, Isaacs C. Jayasekera J, et al. Among authors: schwartz md. J Clin Oncol. 2023 Feb 1;41(4):859-870. doi: 10.1200/JCO.22.01342. Epub 2022 Dec 1. J Clin Oncol. 2023. PMID: 36455167 Free PMC article.

2

Spiritual faith and genetic testing decisions among high-risk breast cancer probands.

Schwartz MD, Hughes C, Roth J, Main D, Peshkin BN, Isaacs C, Kavanagh C, Lerman C. Schwartz MD, et al. Cancer Epidemiol Biomarkers Prev. 2000 Apr;9(4):381-5. Cancer Epidemiol Biomarkers Prev. 2000. PMID: 10794482

3

Effects of coping style and BRCA1 and BRCA2 test results on anxiety among women participating in genetic counseling and testing for breast and ovarian cancer risk.

Tercyak KP, Lerman C, Peshkin BN, Hughes C, Main D, Isaacs C, Schwartz MD. Tercyak KP, et al. Among authors: schwartz md. Health Psychol. 2001 May;20(3):217-22. Health Psychol. 2001. PMID: 11403219

4

Impact of educational print materials on knowledge, attitudes, and interest in BRCA1/BRCA2: testing among Ashkenazi Jewish women.

Schwartz MD, Benkendorf J, Lerman C, Isaacs C, Ryan-Robertson A, Johnson L. Schwartz MD, et al. Cancer. 2001 Aug 15;92(4):932-40. doi: 10.1002/1097-0142(20010815)92:4<932::aid-cncr1403>3.0.co;2-q. Cancer. 2001. PMID: 11550168 Clinical Trial.

5

Impact of BRCA1/BRCA2 mutation testing on psychologic distress in a clinic-based sample.

Schwartz MD, Peshkin BN, Hughes C, Main D, Isaacs C, Lerman C. Schwartz MD, et al. J Clin Oncol. 2002 Jan 15;20(2):514-20. doi: 10.1200/JCO.2002.20.2.514. J Clin Oncol. 2002. PMID: 11786581

6

Breast and ovarian cancer screening practices in healthy women with a strong family history of breast or ovarian cancer.

Isaacs C, Peshkin BN, Schwartz M, Demarco TA, Main D, Lerman C. Isaacs C, et al. Breast Cancer Res Treat. 2002 Jan;71(2):103-12. doi: 10.1023/a:1013800409238. Breast Cancer Res Treat. 2002. PMID: 11881908

7

Utilization of breast cancer screening in a clinically based sample of women after BRCA1/2 testing.

Peshkin BN, Schwartz MD, Isaacs C, Hughes C, Main D, Lerman C. Peshkin BN, et al. Among authors: schwartz md. Cancer Epidemiol Biomarkers Prev. 2002 Oct;11(10 Pt 1):1115-8. Cancer Epidemiol Biomarkers Prev. 2002. PMID: 12376518

8

Bilateral prophylactic oophorectomy and ovarian cancer screening following BRCA1/BRCA2 mutation testing.

Schwartz MD, Kaufman E, Peshkin BN, Isaacs C, Hughes C, DeMarco T, Finch C, Lerman C. Schwartz MD, et al. J Clin Oncol. 2003 Nov 1;21(21):4034-41. doi: 10.1200/JCO.2003.01.088. J Clin Oncol. 2003. PMID: 14581427

9

Tamoxifen as chemoprevention in BRCA1 and BRCA2 mutation carriers with breast cancer: a pilot survey of physicians.

Peshkin BN, Isaacs C, Finch C, Kent S, Schwartz MD. Peshkin BN, et al. Among authors: schwartz md. J Clin Oncol. 2003 Dec 1;21(23):4322-8. doi: 10.1200/JCO.2003.02.107. J Clin Oncol. 2003. PMID: 14645421

10

Short-term impact of cancer prevention and screening activities on quality of life.

Cullen J, Schwartz MD, Lawrence WF, Selby JV, Mandelblatt JS. Cullen J, et al. Among authors: schwartz md. J Clin Oncol. 2004 Mar 1;22(5):943-52. doi: 10.1200/JCO.2004.05.191. J Clin Oncol. 2004. PMID: 14990651 Review.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

397 results

Search Page